Median time to progression with everolimus and placebo was 3.0 months and 2.6 months , respectively ( HR , 0.93 ; 95 % CI , 0.75-1 .15 ) , and disease control rate was 56.1 % and 45.1 % , respectively ( P = .01 ) .